Improving on effective antiretroviral therapy: how good will a cure have to be?

Kenneth A Freedberg^{1

2}, Paul E Sax³

Affiliations

¹ Medical Practice Evaluation Center and Divisions of General Internal Medicine and Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
³ Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

PMID: 27920163
PMCID: PMC5269517
DOI: 10.1136/medethics-2016-103907

Editorial

Improving on effective antiretroviral therapy: how good will a cure have to be?

Kenneth A Freedberg et al. J Med Ethics. 2017 Feb.

. 2017 Feb;43(2):71-73.

doi: 10.1136/medethics-2016-103907. Epub 2016 Dec 5.

Authors

Kenneth A Freedberg^{1

2}, Paul E Sax³

Affiliations

¹ Medical Practice Evaluation Center and Divisions of General Internal Medicine and Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
² Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
³ Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

PMID: 27920163
PMCID: PMC5269517
DOI: 10.1136/medethics-2016-103907

No abstract available

Keywords: HIV Infection and AIDS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Cited by

Despite Gains, the War on HIV Is Far From Over: With No Cure in Sight, Experts Urge Early Diagnosis and Prompt Treatment With Better Adherence.
Worley SL. Worley SL. P T. 2018 Jan;43(1):40-57. P T. 2018. PMID: 29290675 Free PMC article.
Ethics of HIV cure research: an unfinished agenda.
Dubé K, Kanazawa J, Taylor J, Dee L, Jones N, Roebuck C, Sylla L, Louella M, Kosmyna J, Kelly D, Clanton O, Palm D, Campbell DM, Onaiwu MG, Patel H, Ndukwe S, Henley L, Johnson MO, Saberi P, Brown B, Sauceda JA, Sugarman J. Dubé K, et al. BMC Med Ethics. 2021 Jun 30;22(1):83. doi: 10.1186/s12910-021-00651-1. BMC Med Ethics. 2021. PMID: 34193141 Free PMC article. Review.
"We Need to Deploy Them Very Thoughtfully and Carefully": Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States-A Qualitative Inquiry.
Dubé K, Evans D, Dee L, Sylla L, Taylor J, Skinner A, Weiner BJ, Greene SB, Rennie S, Tucker JD. Dubé K, et al. AIDS Res Hum Retroviruses. 2018 Jan;34(1):67-79. doi: 10.1089/AID.2017.0067. Epub 2017 Jul 10. AIDS Res Hum Retroviruses. 2018. PMID: 28562069 Free PMC article.
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV.
Han K, Benn P, Sievers J, Dorey D, Warwick-Sanders M, Hareedy R, Harkness L, Leemereise C, Offenbecker K, Donatti C, Brimhall DB, Schwabe C, Boyle C, Hassman MA, Knowles S, D'Amico R, Spreen WR. Han K, et al. Clin Pharmacol Drug Dev. 2025 Jul;14(7):528-541. doi: 10.1002/cpdd.1538. Epub 2025 Apr 29. Clin Pharmacol Drug Dev. 2025. PMID: 40296638 Free PMC article. Clinical Trial.
Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States.
Dubé K, Kanazawa J, Dee L, Taylor J, Sauceda JA, Gianella S, Smith D, Deeks SG, Peluso MJ. Dubé K, et al. AIDS Res Ther. 2021 Oct 18;18(1):75. doi: 10.1186/s12981-021-00401-8. AIDS Res Ther. 2021. PMID: 34663375 Free PMC article.

References

1. Rodger AJ, Lodwick R, Schechter M, et al. . Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013;27:973–9. 10.1097/QAD.0b013e32835cae9c - DOI - PubMed
1. Drummond MF, Sculpher MJ, Torrance GW, et al. . Methods for the economic evaluation of health care programmes. 3rd edn. Oxford: Oxford University Press, 2005.
1. Walensky RP, Ross EL, Kumarasamy N, et al. . Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med 2013;369:1715–25. 10.1056/NEJMsa1214720 - DOI - PMC - PubMed
1. Sax PE, Sypek A, Berkowitz BK, et al. . HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS ONE 2014;9:e113031 10.1371/journal.pone.0113031 - DOI - PMC - PubMed
1. Ubel PA, Hirth RA, Chernew ME, et al. . What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163:1637–41. 10.1001/archinte.163.14.1637 - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Improving on effective antiretroviral therapy: how good will a cure have to be?

Affiliations

Improving on effective antiretroviral therapy: how good will a cure have to be?

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical